New research challenges notion of using Herceptin only for HER2-positive breast cancer

February 26, 2013, University of Michigan Health System
This image shows Max S. Wicha, M.D., University of Michigan Comprehensive Cancer Center. Credit: University of Michigan Comprehensive Cancer Center

New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative – and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.

About 20 percent of women with have tumors labeled HER2-positive. And since the drug Herceptin has come on the scene, it has had a tremendous impact on survival for these women, particularly when it is given in the adjuvant setting, after surgery to remove the primary cancer. The new findings have potential implications for an additional 65 percent of women with breast cancer.

A recent study based on new analyses of old data found some tumors were incorrectly categorized as HER2-positive and as a result those women received adjuvant Herceptin. It turns out, they benefited as much from the treatment as woman with actual HER2-positive cancer.

"We now provide a molecular explanation for the surprising finding that adjuvant Herceptin benefited some women with HER2-negative breast cancer. If this is confirmed in , it could alter our approach to ," says study author Max S. Wicha, M.D., distinguished professor of and director of the U-M Comprehensive Cancer Center.

At this point, patients with HER2-negative breast cancer are not advised to take Herceptin.

The explanation is that HER2 is selectively expressed in the cancer stem cells of many HER2-negative . Because the stem cells represent such a small number of cells in a tumor, the amount of HER2 is not high enough to meet the threshold for a HER2-positive cancer.

The researchers had previously shown HER2 plays an important role in cancer stem cells – the small number of cells in a tumor that fuel its growth and spread. These cells represent 1 percent to 5 percent of all the cells in a tumor. They are resistant to current chemotherapy and radiation treatments – but since they express HER2, they are effectively targeted by Herceptin.

Further, the researchers in this new study found that for tumors classified as HER2-negative, HER2 levels were higher in bone metastases compared to the primary breast tumor. Bone is the most frequent site to which breast cancer spreads.

The researchers administered Herceptin to mice with these bone lesions and found that it was most effective when given early, when tumors were small or mere "micrometastases." In these cases, Herceptin almost completely blocked the tumors from growing. When the drug was given later, after tumors were established, it had little effect.

"We have shown that the bone microenvironment induces expression in these tumors. If can target bone micrometastases, then administering it to patients before metastases develop could help reduce tumor recurrence," says study author Hasan Korkaya, Ph.D., research assistant professor of internal medicine at the U-M Medical School.

The implications of this finding are that we need cancer treatments that target the small number of cancer stem cells in addition to traditional chemotherapies that eliminate the bulk tumor cells. This means that merely looking at whether a tumor shrinks is not good enough to determine whether the treatment will have long term benefit.

"This work has very significant implications for how we have developed adjuvant therapies. The idea of using drugs that cause tumors to shrink, which has been the accepted paradigm for developing therapies, is flawed. Our work suggests that adjuvant therapies will need to target the cancer stem cell population. Eliminating cancer by effective adjuvant therapies should prevent recurrence, ultimately resulting in more cures," Wicha says.

Explore further: New therapy for HER2-positive breast cancer developed

More information: Reference: Cancer Research, published online Feb. 26, 2013

Related Stories

New therapy for HER2-positive breast cancer developed

July 26, 2011
Patients with HER2-positive breast cancer may soon have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin, according to a laboratory finding published in Clinical Cancer Research.

Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment

July 19, 2012
Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start ...

The HER2 paradox: HER2-positive stem cells found in HER2-negative breast cancer

December 14, 2012
A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis ...

Enhancing the effectiveness of a breast cancer treatment

February 13, 2012
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. ...

Recommended for you

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.